STING1 and neoplasm: (2022) demonstrated that gut microbial metabolites can interfere with radiotherapy-induced cGAS-STING pathway in DCs, subsequently weakening antigen presentation and T cell function, ultimately compromising the anti-tumor immune efficacy of radiotherapy (141).